Laparoscopic Devices – Market Insights – Japan

The Japanese laparoscopic device market will expand modestly through 2035 because demand for MIS procedures will rise in line with the country’s rapidly aging population. The adoption of innovative, premium-priced technologies—including multifunctional direct energy devices that combine ultrasonic and advanced bipolar energies, powered staplers, and 4K video laparoscopes—will further support market growth. However, limited reimbursement for disposable devices and declining ASPs will constrain overall market expansion.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for laparoscopic devices in Japan from 2019 through 2035.

The Japanese laparoscopic device market will grow modestly over the forecast period.

What factors are driving and limiting the laparoscopic device market in Japan?

Which laparoscopic device segment will experience the strongest growth over the forecast period?

RAS will account for an increasing proportion of MIS, limiting demand for traditional laparoscopy.

Which laparoscopic procedures are most affected by the growing adoption of robotic-assisted surgery and are approaching saturation in terms of laparoscopic penetration?

Which laparoscopic procedures currently exhibit the highest penetration levels and continue to demonstrate growth despite the increasing adoption of robotic-assisted surgery?

Adoption of premium-priced technologies is driving growth in the laparoscopic device market.

Which premium laparoscopic technologies will see increased physician adoption during the forecast period?

Which device segments will show the highest growth in Japan?

GLP-1 receptor agonists have experienced rapid adoption among the patient population in Japan in recent years.

Considering the emergence of pharmacological therapies in the pipeline, what is the outlook for bariatric surgery procedure volumes?

How has the rise in GLP-1 receptor agonist prescriptions affected the laparoscopic device market in Japan?

Will the laparoscopic device market recover from the increasing use of GLP-1 receptor agonists, and if so, over what timeframe?